Amneal Pharmaceuticals(AMRX)今日盘中股价大跌8.65%,引发市场广泛关注。公司近期公布的2024年第四季度财报显示,尽管销售额同比大涨18.4%至7.3052亿美元,高于市场预期,但每股收益仅为0.12美元,同比下滑14.3%,低于预期的0.15美元。
利润增长乏力引发了投资者对公司未来获利能力的担忧。AMRX预计2025年全年净收入为30亿至31亿美元,调整后每股收益为0.65至0.70美元,略高于市场预期,但仍显示出营收和利润增长放缓的趋势。在近期行业竞争加剧以及成本上涨的大环境下,投资者显然对制药企业的盈利前景持谨慎态度。
不过,公司管理层对成本控制和新产品推出等多项举措抱有信心,预计这将有助于改善AMRX的经营业绩。但投资者似乎暂时仍没有从最新财报中获得足够信心,导致AMRX股价今日承压大跌。公司未来如何向市场证明稳健的盈利增长,或将成为其证明自身内在价值的关键所在。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.